Navigation Links
ChemoCentryx Reports Positive Phase I Study Results for CCX354 at the Annual European Congress of Rheumatology (EULAR)
Date:6/17/2010

MOUNTAIN VIEW, Calif., June 17 /PRNewswire/ -- ChemoCentryx, Inc., today announced that it reported positive Phase I results for its novel drug candidate CCX354 at the Annual European Congress of Rheumatology (EULAR).  CCX354 is the Company's orally-active small molecule drug candidate designed to specifically target the CCR1 chemokine receptor for the treatment of patients with rheumatoid arthritis (RA).  Data demonstrating that CCX354 was safe and well tolerated with a clear pharmacokinetic to pharmacodynamic relationship were presented today by Daniel Dairaghi, Ph.D., Director, Molecular Pharmacology of ChemoCentryx, in a poster presentation entitled "A Novel CCR1 Antagonist CCX354-C for Rheumatoid Arthritis" in Rome, Italy.  CCX354 is currently in Phase II clinical trials for the treatment of patients with RA.

Study results showed that CCX354 was well tolerated and displayed a linear dose-exposure profile in single-dose and multiple-dose Phase I studies in healthy volunteers.  Plasma levels far exceeded those required for adequate receptor blockade.  High levels of receptor coverage (>90%) at the 12-hour time point were achieved after a single dose of 100 mg of CCX354.

"Our data and the reports of other labs now show that a high degree of CCR1 receptor coverage is essential to achieve a therapeutic effect in inflammatory diseases such as RA," stated Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx.  "We are very pleased that this study demonstrated the unique ability of CCX354 to selectively and sufficiently block the CCR1 receptor – objectives that other molecules in this class have been unable to achieve to date.   As such, we believe our CCR1 antagonis
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth
2. ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 Into Clinical Development
3. ChemoCentryx Identifies Novel Small Molecule C5aR Antagonist
4. ChemoCentryxs Traficet-EN(TM) Phase II/III Induction Phase Data in Crohns Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week
5. ChemoCentryx President and CEO, Thomas J. Schall, Ph.D., Named Ernst & Young Entrepreneur Of The Year 2010 Award Finalist in Northern California
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. QMed, Inc. Reports July Medicare SNP Enrollments
8. Phlo Affiliate Reports Expanded Coverage to Oregon Border
9. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Carrington Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... “Our nation's healthcare system is ... disgrace. Furthermore, every governmental and professional entity that ... state of unorganized dysfunction shares in that enormous ... serve as a device to use in an ... that have accumulated through the years leading to ...
(Date:8/21/2014)... international research team including DESY scientists has observed tiny ... team reports in the journal Science that ... inside the nanodroplets. It is the first time that ... larger samples of what is known as superfluid helium, ... our best expectations," says Andrey Vilesov of the University ...
(Date:8/21/2014)... COLD SPRING, N.Y. , Aug. 21, 2014 ... today the launch of their Nutraceutical "TELO-20 for ... first and only Telomere-lengthening supplement in the world ... the ends of every chromosome in the body. ... the world,s leading experts in Telomere Science and ...
(Date:8/21/2014)... 21, 2014 OTC Markets Group ... a biotechnology company, on its approval to list ... on OTCQX®, the best marketplace for established U.S. ... Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... execution of its growth strategy and achievement of ...
Breaking Biology Technology:5 Great Mistakes in Healthcare and How to Fix Them by Dr. Ira Williams 2Scientists observe quantum vortices in cold helium droplets 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2
... Inc.,(Nasdaq: VRML ), a molecular diagnostics company, ... its board of directors. Mr. Hamilton is,the former ... Inc., a,specialty pharmaceutical company., "John brings more ... strategic and audit matters to Vermillion. His solid ...
... Interim Leadership Responsibility, PRINCETON, N.J., April 10 ... the discovery and development of novel,small molecule therapeutics, ... as President and Chief Executive Officer and a ... pursue other interests. His resignation was,effective April 9, ...
... SEATTLE, April 10 Amnis Corporation announced today ... analysis software.,IDEAS version 3.0 incorporates greatly expanded analytical ... IDEAS 3.0 provides the user with dozens ... to strengthen morphological,data analysis. The new software also ...
Cached Biology Technology:Vermillion Announces Appointment of John Hamilton to Board of Directors 2Leslie J. Browne Resigns as President and Chief Executive Officer of Pharmacopeia, Inc. 2Leslie J. Browne Resigns as President and Chief Executive Officer of Pharmacopeia, Inc. 3Leslie J. Browne Resigns as President and Chief Executive Officer of Pharmacopeia, Inc. 4Amnis Announces Release of Powerful New Image Data Analysis Software 2
(Date:8/22/2014)... antioxidants and can reduce free radical damage. ... oxidative stress? Jianbo Zhao and co-workers from ... University, China discovered that green tea polyphenol ... apoptosis, indicating green tea polyphenols play a ... oxidative stress. The relevant study has been ...
(Date:8/21/2014)... smog-producing toxins in past decade, GTA still violates ... that while the Greater Toronto Area (GTA) has ... to smog, the city continues to violate the ... can cause or aggravate health problems such as ... a set of complex photochemical reactions involving volatile ...
(Date:8/21/2014)... dandruff, eczema and other itchy, flaky maladies in humans ... Hawaiian coral reefs and the extreme environments of arctic ... the scientific journal PLOS Pathogens considers the ... genus Malassezia in light of new insights ... world. , University of Hawai,i at Mānoa scientist Anthony ...
Breaking Biology News(10 mins):Despite a significant reduction in smog-producing toxins, the Greater Toronto Area still violates Canada's standards for ozone air pollution 2From dandruff to deep sea vents, an ecologically hyper-diverse fungus 2
... and Amsterdam, The Netherlands, January 14, 2008 A ... E genotypes has been developed by researchers from the ... Southern Medical University, Guangzhou, China. This assay combines PCR ... genotyping of the human population, which in turn will ...
... have a skull that functioned like a fish-eating crocodile, despite ... claws, perhaps used as grappling hooks to lift fish from ... Bristol, UK, used computer modelling techniques more commonly used ... to show that while Baryonyx was eating, its skull ...
... 20,000 people found seven new genes that influence blood ... confirmed 11 other genes previously thought to influence ... from the University of Michigan School of Public Health ... influence lipid levels, and secondly, to see if those ...
Cached Biology News:New method developed to identify genetic determinants of Alzheimer's disease 2Unusual fish-eating dinosaur had crocodile-like skull 2Study locates cholesterol genes; finds surprises about good, bad cholesterol 2
geminin, DNA replication inhibitor...
Normal human serum, single donor...
One-step, microplate or cuvet, colorimetric, linear detection range 0.1 mg/dL to 100 mg/dL. Procedure: 20 min....
... Certified USDA Research Registered OLAW Assured AAALAC ... AALAS Certified Technicians Documentation ... Upon Request Focus CRP is ... your custom immunology service needs. We ...
Biology Products: